Characteristics of 25 patients who received blinatumomab mAb1 and inotuzumab mAb2 stratified according to the receipt of other interim therapy between mAb1 and mAb2
| Characteristic . | All (N = 25) . | No interim therapy (n = 12) . | Received interim therapy (n = 13) . | P . |
|---|---|---|---|---|
| Median age at diagnosis (IQR, y) | 43.6 (24.4-60.7) | 42.0 (21.2-65.0) | 43.6 (32.4-47.6) | .46 |
| Age >45 y | 12 (48.0%) | 6 (50.0%) | 6 (46.2%) | .84 |
| Male sex | 13 (52.0%) | 5 (41.7%) | 8 (61.5%) | .32 |
| Median number of prior lines of therapy before blinatumomab (range, lines) | 1 (1-5) | 2 (1-3) | 1 (1-5) | .04 |
| Prior alloHSCT before mAb1 | 3 (12.0%) | 1 (8.3%) | 2 (15.4%) | 1.00 |
| High-risk cytogenetic abnormalities | 10 (40.0%) | 4 (33.3%) | 6 (46.2%) | .21 |
| Philadelphia chromosome positive | 4 (16.0%) | 3 (25.0%) | 1 (7.1%) | .32 |
| Presence of MLL rearrangement | 1 (4.0%) | 1 (8.3%) | 0 (0.0%) | 1.00 |
| Disease burden at the time of blinatumomab mAb1 | .59 | |||
| MRD | 7 (28.0%) | 4 (33.3%) | 3 (23.1%) | |
| Morphologic disease | 18 (72.0%) | 8 (66.7%) | 10 (76.9%) | |
| Site of disease at the time of blinatumomab mAb1 | .78 | |||
| Isolated marrow | 21 (84.0%) | 10 (83.3%) | 11 (84.6%) | |
| Isolated extramedullary | 1 (4.0%) | 0 (0.0%) | 1 (7.7%) | |
| Both | 3 (12.0%) | 2 (16.7%) | 1 (7.7%) | |
| Median no. of blinatumomab mAb1 cycles (range, cycles) | 1 (1-6) | 1 (1-6) | 1 (1-4) | .53 |
| Best response to blinatumomab mAb1 | .32 | |||
| CR | 13 (52.0%) | 5 (41.7%) | 8 (61.5%) | |
| No response | 12 (48.0%) | 7 (58.3%) | 5 (38.5%) | |
| Median time from blinatumomab to progression/relapse (IQR, d) | 73 (34-219) | 65 (37-118) | 73 (33-290) | .85 |
| Site of disease at the time of relapse following blinatumomab mAb1 | .41 | |||
| Isolated marrow | 15 (60.0%) | 8 (66.7%) | 7 (53.8%) | |
| Isolated extramedullary | 1 (4.0%) | 1 (8.3%) | 0 (0.0%) | |
| Both | 9 (36.0%) | 3 (25.0%) | 6 (46.2%) | |
| Central nervous system involvement at the time of relapse after blinatumomab mAb1 | 1 (4.0%) | 0 (0.0%) | 1 (7.7%) | .48 |
| Response to inotuzumab mAb2 | .89 | |||
| CR | 17 (68.0%) | 8 (69.2%) | 9 (69.2%) | |
| No response | 8 (32.0%) | 4 (30.8%) | 4 (30.8%) |
| Characteristic . | All (N = 25) . | No interim therapy (n = 12) . | Received interim therapy (n = 13) . | P . |
|---|---|---|---|---|
| Median age at diagnosis (IQR, y) | 43.6 (24.4-60.7) | 42.0 (21.2-65.0) | 43.6 (32.4-47.6) | .46 |
| Age >45 y | 12 (48.0%) | 6 (50.0%) | 6 (46.2%) | .84 |
| Male sex | 13 (52.0%) | 5 (41.7%) | 8 (61.5%) | .32 |
| Median number of prior lines of therapy before blinatumomab (range, lines) | 1 (1-5) | 2 (1-3) | 1 (1-5) | .04 |
| Prior alloHSCT before mAb1 | 3 (12.0%) | 1 (8.3%) | 2 (15.4%) | 1.00 |
| High-risk cytogenetic abnormalities | 10 (40.0%) | 4 (33.3%) | 6 (46.2%) | .21 |
| Philadelphia chromosome positive | 4 (16.0%) | 3 (25.0%) | 1 (7.1%) | .32 |
| Presence of MLL rearrangement | 1 (4.0%) | 1 (8.3%) | 0 (0.0%) | 1.00 |
| Disease burden at the time of blinatumomab mAb1 | .59 | |||
| MRD | 7 (28.0%) | 4 (33.3%) | 3 (23.1%) | |
| Morphologic disease | 18 (72.0%) | 8 (66.7%) | 10 (76.9%) | |
| Site of disease at the time of blinatumomab mAb1 | .78 | |||
| Isolated marrow | 21 (84.0%) | 10 (83.3%) | 11 (84.6%) | |
| Isolated extramedullary | 1 (4.0%) | 0 (0.0%) | 1 (7.7%) | |
| Both | 3 (12.0%) | 2 (16.7%) | 1 (7.7%) | |
| Median no. of blinatumomab mAb1 cycles (range, cycles) | 1 (1-6) | 1 (1-6) | 1 (1-4) | .53 |
| Best response to blinatumomab mAb1 | .32 | |||
| CR | 13 (52.0%) | 5 (41.7%) | 8 (61.5%) | |
| No response | 12 (48.0%) | 7 (58.3%) | 5 (38.5%) | |
| Median time from blinatumomab to progression/relapse (IQR, d) | 73 (34-219) | 65 (37-118) | 73 (33-290) | .85 |
| Site of disease at the time of relapse following blinatumomab mAb1 | .41 | |||
| Isolated marrow | 15 (60.0%) | 8 (66.7%) | 7 (53.8%) | |
| Isolated extramedullary | 1 (4.0%) | 1 (8.3%) | 0 (0.0%) | |
| Both | 9 (36.0%) | 3 (25.0%) | 6 (46.2%) | |
| Central nervous system involvement at the time of relapse after blinatumomab mAb1 | 1 (4.0%) | 0 (0.0%) | 1 (7.7%) | .48 |
| Response to inotuzumab mAb2 | .89 | |||
| CR | 17 (68.0%) | 8 (69.2%) | 9 (69.2%) | |
| No response | 8 (32.0%) | 4 (30.8%) | 4 (30.8%) |
MLL, mixed lymphoid lineage.